ReviewBMC rheumatology2017
Giant cell arteritis: pathogenic mechanisms and new potential therapeutic targets.
Review in BMC rheumatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 52 citations in OpenAlex.
- Genome-Wide DNA Methylation Study Reveals Specific Signatures in the Affected Arterial Tissue of Patients With Giant Cell Arteritis.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Mature CD209Scientific reports · 2025Article
- Severe renal haemosiderosis in a patient with untreated paroxysmal nocturnal haemoglobinuria: a case report.BMC nephrology · 2025Article
- Birdshot Chorioretinopathy in a Patient on Tocilizumab for the Treatment of Giant Cell Arteritis.Case reports in ophthalmological medicine · 2025Article
- Illness Burden and Unmet Patient Needs in Giant Cell Arteritis: Current State and Future Prospects.Open access rheumatology : research and reviews · 2025Review
- Optical frequency domain imaging (OFDI) represents a novel technique for the diagnosis of giant cell arteritis.Eye (London, England) · 2024Article
- Concomitant Polymyalgia Rheumatica and Giant Cell Arteritis Associated with Cystic Echinococcosis: A Rare Geriatric Case.Acta parasitologica · 2024Article
- Review
- Current Perspectives in Giant Cell Arteritis: Can We Better Connect Pathogenesis and Treatment?Medicina (Kaunas, Lithuania) · 2024Review
- Giant Cell Arteritis: Advances in Understanding Pathogenesis and Implications for Clinical Practice.Cells · 2024Review
- Comparison of halo and compression signs assessed by a high frequency ultrasound probe for the diagnosis of Giant Cell Arteritis.Journal of ultrasound · 2022Article
- A Giant Silence - An atypical association of sensorineural hearing loss with Giant Cell Arteritis.International journal of rheumatic diseases · 2022Article
- Global Transcriptomic Profiling Identifies Differential Gene Expression Signatures Between Inflammatory and Noninflammatory Aortic Aneurysms.Arthritis & rheumatology (Hoboken, N.J.) · 2022Article
- Plasma Pyruvate Kinase M2 as a marker of vascular inflammation in giant cell arteritis.Rheumatology (Oxford, England) · 2022Article
- Rapid Quantum Magnetic IL-6 Point-of-Care Assay in Patients Hospitalized with COVID-19.Diagnostics (Basel, Switzerland) · 2022Article
- Advances in the Treatment of Giant Cell Arteritis.Journal of clinical medicine · 2022Review
- Pathogenesis of giant cell arteritis with focus on cellular populations.Frontiers in medicine · 2022Review
- Cellular signaling pathways of T cells in giant cell arteritis.Journal of geriatric cardiology : JGC · 2021Article
- Stroke secondary to giant-cell arteritis: A literature review.Experimental and therapeutic medicine · 2021Article
- Biologic Therapies for Giant Cell Arteritis.Biologics : targets & therapy · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Giant cell arteritis (GCA) is the most common idiopathic systemic vasculitis in persons aged 50 years or greater. Treatment options for GCA, to-date, have been limited and have consisted primarily of glucocorticoids. Significant advances in the understanding of the genetic and cellular mechanisms in GCA are leading to identification of potential pathogenic targets. The recent success of interleukin-6 blockade in the treatment of GCA has opened the landscape to targeted biologic therapy. T cells, particularly T helper 1 and T helper 17 cell lineages have been identified as key inflammatory cells in both active and chronic vascular inflammatory lesions. Therapeutic agents, including abatacept and ustekinumab, which can impede both vasculitogenic cell lines are of particular interest. Inhibition of signalling pathways, including the janus kinase-signal tranducers and activation of transcription (JAK-STAT) and Notch pathways are evolving options. Tocilizumab has shown clear benefit in both newly diagnosed and relapsing patients with GCA and approval of this medication for treatment of GCA has led to rapid incorporation into treatment regimens. More information is required to understand the long-term outcomes of tocilizumab and other investigational targeted therapeutics in the treatment of GCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.